Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation
type: MedicalStudy
description: An Open-label, Multicenter, Phase II Study of Capmatinib in Patients With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
status: UNKNOWN
study design: INTERVENTIONAL
phase: PHASE2
start date: 2018-10-30
end date: 2022-06-30
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT03693339
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Asan Medical Center
study subject: Cancer
study subject: Lung Cancer Metastatic
study subject: MET Gene Mutation
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: UNKNOWN
keywords: Cancer
keywords: Lung Cancer Metastatic
keywords: MET Gene Mutation

AI Analytics
type: Organization